TRT and Deep Vein Thrombosis: Understanding the Risk

Written by Adam Maggio | Medically reviewed by Dr. Sarah Chen, PharmD, BCPS

The relationship between testosterone replacement therapy (TRT) and the risk of deep vein thrombosis (DVT) is complex and has been a subject of ongoing research. While some studies suggest a transient increase in DVT risk, particularly early in therapy, larger analyses often show no significant long-term increase, emphasizing the importance of individual risk assessment and careful monitoring.

TRT and Deep Vein Thrombosis: Navigating the Nuances of Blood Clot Risk

Deep vein thrombosis (DVT), a serious condition involving blood clot formation in a deep vein, typically in the legs, is a concern for many patients considering or undergoing testosterone replacement therapy (TRT). The connection between TRT and DVT risk has been a topic of extensive research and debate, with evolving evidence shaping clinical recommendations. It's crucial to understand the current data to make informed decisions.

The Evolving Evidence: Conflicting Signals

Early observational studies and some smaller analyses initially raised concerns about an increased risk of venous thromboembolism (VTE), which includes both DVT and pulmonary embolism (PE), with TRT. For instance, a study by Walker et al. (2020) suggested an increase in short-term VTE risk among men on TRT, both with and without hypogonadism. Similarly, a case-control study by Martinez et al. (2016) indicated that starting testosterone treatment was associated with an increased risk of VTE, peaking within six months of initiation and then declining.

However, more recent and larger studies, including meta-analyses and the landmark TRAVERSE trial, have provided a more nuanced picture. The TRAVERSE trial, a large cardiovascular safety study, did note a higher incidence of pulmonary embolism (0.9% with testosterone vs. 0.5% with placebo), which is a direct consequence of DVT. This finding, while statistically significant, represented a small absolute increase.

Conversely, some large analyses have found no significant increase in DVT risk. A systematic review and meta-analysis of randomized controlled trials by Corona et al. (2024) generally concluded that TRT has a neutral effect on major adverse cardiovascular events (MACE), which often include DVT as a component, when appropriately used in hypogonadal men. Another large analysis mentioned in Urology Times found that middle-aged and older men undergoing TRT were not at an increased risk of VTE overall.

Potential Mechanisms and Contributing Factors

The exact mechanisms by which TRT might influence DVT risk are not fully understood but may involve several factors:

• Erythrocytosis/Polycythemia: As discussed in the previous article, TRT can increase red blood cell count and hematocrit, leading to thicker blood (hyperviscosity), which can promote clot formation. This is a well-established side effect.
• Platelet Aggregation: Some research suggests testosterone may influence platelet function, potentially increasing their aggregation.
• Coagulation Factors: Testosterone might affect various coagulation factors, although the net effect on thrombosis risk is complex and not consistently demonstrated.
• Individual Predisposition: Men with pre-existing risk factors for DVT, such as a history of DVT/PE, inherited thrombophilias (e.g., Factor V Leiden mutation), obesity, prolonged immobility, or certain medical conditions (e.g., cancer), may be more susceptible to TRT-associated DVT.

Clinical Recommendations and Risk Mitigation

Given the conflicting data and the potential for increased risk in certain individuals, clinical practice emphasizes careful patient selection and monitoring:

• Thorough Pre-screening: Before initiating TRT, your doctor should conduct a comprehensive assessment of your personal and family history of DVT/PE and other thrombotic disorders.
• Hematocrit Monitoring: Regular monitoring of hematocrit levels is essential. If polycythemia develops, management strategies (e.g., dose adjustment, phlebotomy) should be implemented promptly to reduce hyperviscosity.
• Patient Education: You should be educated about the symptoms of DVT (e.g., leg pain, swelling, redness) and PE (e.g., sudden shortness of breath, chest pain) and instructed to seek immediate medical attention if they occur.
• Caution in High-Risk Individuals: TRT should be used with caution, or potentially avoided, in men with a strong history of DVT/PE or known thrombophilia.

Unlike the clear benefits of TRT for symptoms of hypogonadism, the DVT risk remains a nuanced area requiring individualized assessment. It's not a universal risk, but a potential complication that demands vigilance.

Practical Takeaway

While the overall risk of deep vein thrombosis (DVT) with TRT is not definitively established as high for all men, it's a serious potential complication that warrants attention. You'll need to discuss your personal and family history of blood clots with your doctor before starting TRT. If you do begin therapy, be vigilant for symptoms like leg pain, swelling, or redness, and report them immediately. Regular monitoring of your blood count, especially hematocrit, is crucial, and your doctor will manage any elevations to minimize your risk. Don't self-medicate or ignore potential symptoms; prompt medical attention is key.